Crystagen Research: One Indexed Study, Stated Plainly
This is the shortest page in this library, and deliberately so. Crystagen is a member of the Khavinson short-peptide family for which exactly one indexed primary study could be located — and that study reports a partial null. Padding this page to look like the others would misrepresent the state of the literature. What follows is the chemistry, the one study, and the gap. Family context is on the peptide bioregulator overview.
What is Crystagen?
What is Crystagen? A synthetic tripeptide of the Khavinson short-peptide programme, given as Glu-Asp-Pro (EDP). The sequence attribution deserves a caveat that most sources do not give it: it rests on a single source — the family table in Khavinson et al. (Int J Mol Sci, 2022, PMID 35887081), which lists “Crystagen (EDP)”. No PubChem record carries “Crystagen” as a listed synonym, and no primary study located writes the sequence out alongside the trade name. Every vendor page repeating “Crystagen is Glu-Asp-Pro” is, as far as this page could determine, repeating that one table.
Reference data
Identity and form only, from the public chemical record for the all-L Glu-Asp-Pro tripeptide (PubChem CID 23624313). This record is not labelled “Crystagen”; it is the chemical entry for the sequence the 2022 review assigns to it.
| Property | Value |
|---|---|
| Peptide class | Tripeptide (3 residues) |
| Sequence | Glu-Asp-Pro (EDP) — single-source attribution, see above |
| Molecular formula | C₁₄H₂₁N₃O₈ |
| Molecular weight | ≈ 359.33 g/mol |
| Physical form | Lyophilized powder |
| Storage | Kept cold and dry as supplied; protected from light |
A CAS number for this sequence could not be sourced from an authoritative record and is therefore omitted rather than guessed. No handling quantity, reconstitution procedure or route is given or implied.
The one study
Chervyakova, Linkova, Chalisova, Koncevaya, Trofimova and Khavinson (2014, Adv Gerontol, PMID 28976144, Russian-language with an English abstract) compared four short peptides — Vilon, Thymogen, Crystagen and one designated R-1 — for immunoprotective effects in ageing spleen. The abstract reports that Crystagen activated the B-cell arm of the immune system in that model, and, in the same sentence, that it did not affect cell-renewal processes in the ageing spleen, where Vilon acted by reducing apoptosis and R-1 by increasing proliferation and differentiation.
That is the located primary record in full. The 2022 family review additionally assigns Crystagen the designation “immunoprotector” and cites it to US Patent 8,057,810 — a patent, not a study. Only the English abstract of the 2014 paper was available for this page; the full text is Russian-language.
Evidence status — what is not established
Almost everything. There is no second study, no independent replication, no human data, no mechanism work specific to this compound, and no sequence confirmation outside a single review table. The one indexed result is mixed rather than positive, and it comes from the compound’s own developers.
A researcher considering this compound should know that they would be working essentially without a literature. That is a legitimate position to be in — plenty of useful chemistry starts there — but it should be entered knowingly rather than on the strength of a family reputation borrowed from better-studied members like Vilon and Epitalon. Nothing on this page is a claim about what this compound does in a person, and material is supplied for laboratory research use only.
How to verify this compound yourself
Given that the identity attribution itself rests on one source, analytical verification matters more here than usual. Mass spectrometry should confirm the measured mass against the expected ≈ 359 Da for Glu-Asp-Pro; if a certificate reports a different mass, the vial is a different molecule from the one this page describes, whatever the label says. HPLC purity is reported as a percentage. See how to read a COA and how to verify peptide purity, and check a specific batch on the verify tool.
Research-grade sourcing and verification
Crystagen is not held in stock. It is listed on our sourcing catalogue as available to order — our supplier lists it, we have not bought it, and material of this kind typically takes about two to three weeks to reach us. For laboratory research use only, it is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation. Related pages: the bioregulator overview, Vilon, Vesugen and Cartalax. This is sourcing and quality-assurance framing only.
Verify a batch
Every order ships with a per-batch Certificate of Analysis. Have a vial in hand? Enter its lot number to look up the COA for that exact batch.
Frequently asked questions
What is Crystagen?
How much research exists on Crystagen?
What did that study report?
Should a researcher treat Crystagen as an established compound?
Literature cited
- Chervyakova NA, Linkova NS, Chalisova NI, Koncevaya EA, Trofimova SV, Khavinson VK. “Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process.” Adv Gerontol. 2014;27(1):224–228. PMID 28976144. pubmed.ncbi.nlm.nih.gov/28976144 (Russian-language; English abstract only; reports a partial null for Crystagen).
- Khavinson V, Linkova N, Kozhevnikova E, et al. “Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers.” Int J Mol Sci. 2022;23(14):7733. PMID 35887081. pubmed.ncbi.nlm.nih.gov/35887081 (sole located source for the Crystagen = EDP sequence assignment; cites the immunoprotector designation to US Patent 8,057,810).
- National Center for Biotechnology Information. “PubChem Compound Summary for CID 23624313, Glu-Asp-Pro.” pubchem.ncbi.nlm.nih.gov/compound/23624313 (formula, mass; record is not labelled Crystagen).
RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION. All products are sold strictly for in-vitro laboratory research and are not intended for human or veterinary use, ingestion, or administration. Nothing on this page is a medical or efficacy claim. You must be 21 or older to browse this catalog.